Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Profit After Tax (2016 - 2025)

Viking Therapeutics' Profit After Tax history spans 12 years, with the latest figure at -$157.7 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 345.16% year-over-year to -$157.7 million; the TTM value through Dec 2025 reached -$359.6 million, down 227.05%, while the annual FY2025 figure was -$359.6 million, 227.05% down from the prior year.
  • Profit After Tax for Q4 2025 was -$157.7 million at Viking Therapeutics, down from -$90.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$12.4 million in Q4 2021 and bottomed at -$157.7 million in Q4 2025.
  • The 5-year median for Profit After Tax is -$20.9 million (2022), against an average of -$34.0 million.
  • The largest annual shift saw Profit After Tax decreased 10.29% in 2023 before it tumbled 345.16% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$12.4 million in 2021, then tumbled by 58.3% to -$19.6 million in 2022, then dropped by 25.8% to -$24.6 million in 2023, then plummeted by 43.94% to -$35.4 million in 2024, then crashed by 345.16% to -$157.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Profit After Tax are -$157.7 million (Q4 2025), -$90.8 million (Q3 2025), and -$65.6 million (Q2 2025).